New hope for HER2+ breast cancer: switching drug combos after treatment fails

NCT ID NCT07455188

Recruiting now Disease control Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated Jun 16, 2026 · Updated 11 times

Summary

This study looks at what happens when people with HER2-positive advanced breast cancer switch between two different targeted therapy combinations after their first treatment stops working. About 600 women will be split into two groups: one switches from HP+chemo to HPy+chemo, the other does the opposite. The goal is to see which switch works better at controlling the cancer and helping people live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhejiang Cancer Hospital
RECRUITING

Zhejiang, Hangzhou, 310000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER